Comparative analysis of hepatitis C virus phylogenies from coding and non-coding regions: the 5' untranslated region (UTR) fails to classify subtypes
© Hraber et al; licensee BioMed Central Ltd. 2006
Received: 06 November 2006
Accepted: 14 December 2006
Published: 14 December 2006
The duration of treatment for HCV infection is partly indicated by the genotype of the virus. For studies of disease transmission, vaccine design, and surveillance for novel variants, subtype-level classification is also needed. This study used the Shimodaira-Hasegawa test and related statistical techniques to compare phylogenetic trees obtained from coding and non-coding regions of a whole-genome alignment for the reliability of subtyping in different regions.
Different regions of the HCV genome yield inconsistent phylogenies, which can lead to erroneous conclusions about classification of a given infection. In particular, the highly conserved 5' untranslated region (UTR) yields phylogenetic trees with topologies that differ from the HCV polyprotein and complete genome phylogenies. Phylogenetic trees from the NS5B gene reliably cluster related subtypes, and yield topologies consistent with those of the whole genome and polyprotein.
These results extend those from previous studies and indicate that, unlike the NS5B gene, the 5' UTR contains insufficient variation to resolve HCV classifications to the level of viral subtype, and fails to distinguish genotypes reliably. Use of the 5' UTR for clinical tests to characterize HCV infection should be replaced by a subtype-informative test.
In treating infection with hepatitis C virus, knowledge of a patient's viral genotype informs the choice of appropriate therapy [1–3]. Although the HCV subtype afflicting a patient is not currently used to make clinical treatment decisions, knowing the viral subtype is important for studies of its origin, transmission, and evolution [1–4]. For example, new emerging variants can be characterized better when they can be assigned an unequivocal subtype classification . Molecular epidemiology analyses rely on information about sequence variation at the subtype level [4, 5]. Vaccine-design strategies are informed by the diversity of HCV variants and the antigenic determinants (epitopes) therein [6, 7]. The risk of hepatocellular carcinoma, a frequent complication for HCV infection, might be assessed better in light of HCV subtype . Thus, effective methods for both genotype and subtype classification are important tools to manage HCV infections.
Techniques to infer phylogenies combine an optimality criterion with an algorithm to search for the best tree. Optimality criteria quantify how well the tree describes the data, and are either distance-based or character-based [9, 10]. An algorithm can quickly construct a single tree that minimizes all the pairwise distances among taxa. However, this approach is less able to use information from different taxa to model variation in evolutionary rates across sites than the optimality criterion of maximum likelihood (, p. 175). Search algorithms are deployed by character-based methods to find trees that best explain the data, given an evolutionary model with known assumptions. The search algorithms of character-based methods take more time to evaluate alternative candidate trees than rapid distance-based methods. Perhaps for this reason, many more distance-based than character-based phylogenies of HCV genotypes have been published. However, maximum-likelihood phylogenetic inference is known to outperform distance-based methods when such complications as substitution rate heterogeneity or covariation between sites are present [9, 10]. Formal comparisons between topologies are thus more appropriate for maximum-likelihood phylogenies than for the approximations that result from distance-based methods.
This study evaluates phylogenies derived from coding (NS5B) and non-coding (5' UTR) regions of whole-genome HCV sequences for consistent classification of viral subtypes into distinct genetic groups, or clades, with the aim of evaluating their suitability for genotype and subtype classification. Concordance with the whole-genome phylogeny is desired. Nucleotide characters in NS5B are over five times more abundant than in the 5' UTR, though only a small portion of this region is amplified for subtyping. To compensate for this, we also considered a smaller, oft-studied portion of NS5B that we call the "Okamoto region" (from nt 8282 to 8610 in the H77 reference genome) for its ability to represent the phylogeny of NS5B and the entire HCV genome. We tested the hypothesis that phylogenetic trees obtained from different genomic regions of HCV differ significantly. We also compared tree topologies for their ability to group genotypes and subtypes consistently into clades.
Confirmed subtypes and accession numbers of HCV genomes studied.
Database Accession Numbers
[EMBL:AF009606, EMBL:AF511950, EMBL:D10749, EMBL:M62321]
[EMBL:AF483269, EMBL:AJ000009, EMBL:D11168, EMBL:L02836]
[EMBL:AY051292, EMBL:AY651061, EMBL:D14853, EMBL:E08443]
[EMBL:AB047639, EMBL:AF169003, EMBL:AF169005, EMBL:D00944]
[EMBL:AB030907, EMBL:AF238486, EMBL:AY232746, EMBL:D10988]
[EMBL:AF046866, EMBL:D17763, EMBL:D28917, EMBL:X76918]
Substitution model (GTR+Γ+I) parameters and alignment properties.
Proportion of invariant sites (I)
Γ-distribution shape parameter
Nucleotides in alignment
Conserved sites in alignment
The 5' UTR is represented by the smallest number of aligned nucleotide sites (300 nt; the 5' most 42 nt were excluded from analysis because of extensive gaps throughout the available sequence data), followed by the Okamoto region of NS5B (329 nt), then the polyprotein (9177 nt), and the whole genome (9791 nt, Table 2). The proportion of invariant nucleotide sites for the 5' UTR is 2/3, much lower than for the protein-coding regions, for which less than 1/3 of sites do not vary (Table 2). The 5' UTR is known to be less variable than protein-coding regions of HCV [3, 6, 11, 12].
Shimodaira-Hasegawa test results from 10,000 bootstrap replicates.
5' UTR sites
Okamoto region sites
Consistency and homoplasy indices
An earlier investigation of phylogenetic relations among 27 complete HCV genomes used maximum likelihood and careful determination of the appropriate nucleotide substitution model, and reported a star-like phylogeny among the six known HCV genotypes . The best substitution model was also found to be the most general. In the earlier study, the 5' UTR was found to have lower phylogenetic signal, lower evolutionary rate, and greater phylogenetic noise than alternative regions of the HCV genome, including NS5B . Our observations concur with those previously reported. Methodological refinements in our approach include the use of information-based model selection criteria to determine the best nucleotide substitution model, more complete HCV genomes, the revised nomenclature for subtypes , and formal comparisons between alternative topologies for the purpose of subtype determination.
The tree from the Okamoto region of NS5B is a significantly better fit to the HCV whole-genome and polyprotein data than the 5' UTR tree, regardless of the optimality criterion used for phylogenetic inference. Trees obtained from the 5' UTR perform worse at classifying HCV subtypes into clades of the same genotype than do trees from the whole genome, polyprotein, or the Okamoto region of NS5B. Discordant topologies of maximum-likelihood phylogenetic trees obtained from the 5' UTR and NS5B have been described for a subset of HCV genotypes [14, 15]. The inconsistent ordering of deeply rooted branches among trees from protein-coding regions indicates a basal polytomy whose resolution is contingent on the data available, which accords with the star-like phylogeny of all six known HCV genotypes previously reported elsewhere [3, 5, 12, 16].
The same evolutionary model (GTR with a discrete-gamma distribution of rate variation) used here has been utilized previously for likelihood phylogenies of the hepatitis B virus  and, with accommodation of invariant sites, for both HIV  and HCV . Instantaneous substitution rates (normalized to the G-U rate) are greater among sites in the non-coding 5' UTR than in the regions that encode proteins, despite the fact that overall sequence conservation is greater in the UTR (Table 2). In particular, the instantaneous substitution rate between cytidine and uridine is much greater for the 5' UTR than for protein-coding regions. The accelerated C-U (or C-T for DNA sequences) substitution rate has previously been reported and discussed for protein-coding regions , though the rate is even greater for the non-coding terminus than for regions having codon usage constraints. Spontaneous deamination of cytosine to uracil may inflate the C-U substitution rate.
Conservation of single-stranded RNA secondary structure in both coding and non-coding regions of HCV has already been reported [15, 20–23]. The high C-U rate bias may additionally be explained by the formation of non-canonical base pairs between guanosine and uridine in single-stranded RNA molecules, which is consistent with selection to conserve secondary structure, because a mutation from cytosine to uridine is less disruptive to secondary structure formation than other point mutations . The may also be explained by the fact that all rates are rescaled such that the G-U rate is unity. A low G-U substitution rate thus inflates other rates. A mutation between G and U is disruptive to RNA secondary structure, because it eliminates the possibility of bases pairing without a compensatory mutation elsewhere. Overall, the elevated C-U substitution rate seen for the 5' UTR probably results from several interacting factors.
Though the same evolutionary model applies to the non-coding 5' UTR and the Okamoto region of NS5B, the two regions are subjected to different constraints. While coding sequences have codon-usage constraints and selective pressure for amino-acid mutations to escape detection by the host immune system, the UTR must preserve long-range interactions with complementary nucleotides at the other terminus of the viral genome if cyclization of the genome is essential to viral replication [6, 20]. Because of these differences in selective regimes, it should not be surprising that phylogenies of the two differ.
HCV diagnostic technologies include serologic (antibody based) and genetic (sequence based) techniques to detect infected samples [4, 6, 25]. Population screens are the most commonly deployed genetic HCV tests, which benefit from low false-positive rates because they utilize the conserved 5' UTR as targets for PCR amplification. However, it is clear both from the results of this study and from previous investigations that the 5' UTR does not contain sufficient information to resolve subtypes [26–31]. Phylogenetic signal in protein-coding regions, such as NS5B, provides a useful alternative [12, 32], but few commercial assays exploit this information at present. The "gold standard" for subtype determination is direct sequencing, which has a lower cost for reagents but requires more time than commercial assay kits [4, 25].
There exist further complications to subtype classification, including coinfection [30, 33, 34], recombination [35, 36], within-host evolution [37, 38], and compartmentalization of genotypes into different cell types . Diagnostic assays that are informed by the 5' UTR will be less able to accommodate these difficulties than methods that are able to resolve subtypes.
Ultimately, HCV infection outcome results from an interaction between the virus and its host. The current standard of care is limited in efficacy, and treatment outcome is contingent on viral genotype [1–3, 6, 25, 34]. To improve HCV therapies, perform effective public-health surveillance for new variants and modes of transmission, and further vaccine development efforts, detailed information about the interacting genotypes is needed. Diagnostic methods that assign viral subtype classifications are thus greatly desired. Such methods perform better when they are not informed by sequence variation from the non-coding 5' UTR, and should instead favor protein-coding regions, such as the Okamoto region of NS5B.
We used multiple methods for phylogenetic inference, including neighbor joining (NJ), maximum parsimony (MP), and maximum likelihood (ML) [9, 10]. This was done to evaluate whether the inferential technique has an influence on the ability of the resulting phylogenies to resolve subtypes into clades. We used PAUP*, version 4.0b10  for phylogenetic inference. Neighbor-joining trees were constructed with the F84 distance metric  and the BioNJ algorithm . For parsimony analyses, uninformative invariant characters were excluded and gaps were treated as a fifth character state.
To select an appropriate nucleotide substitution model, we used FindModel, an independ-ent, online implementation of ModelTest . This approach uses an information-based goodness-of-fit criterion, in the sense that the best model minimizes the quantity of bits required to encode both the model and the model-encoded data for electronic transmission [44–46]. Such an approach includes a penalty term for the number of parameters, and thus facilitates comparing models with varied numbers of parameters . The fit of each model to the data was evaluated both with and without a four-category discrete approximation to a gamma distribution of substitution rates per site. Because FindModel does not test models with invariant sites, we also used ModelTest (version 3.6) to evaluate nucleotide substitution models with invariant sites . Akaike's information criterion (AIC) was used to quantify the suitability of alternative models having varied numbers of parameters to fit the data .
To evaluate the significance of differences in ML phylogenies obtained from different regions of the HCV genome, we used the Shimodaira-Hasegawa (SH) test  as implemented in PAUP*, version 4.0b10 . The null hypothesis of the SH test is that none of the trees evaluated has a likelihood that differs significantly from any other. Rejecting the null hypothesis indicates a significant difference in likelihood scores, and thus in tree topologies .
For a pair of trees defined a priori, the SH test computes the difference in their likelihoods (Δ). This difference is compared with the null distribution of likelihood scores, obtained by building trees from character data generated by iterative bootstrap resampling with replacement of the nucleotide sites. A computationally efficient optimization (RELL) may be applied, which simply adds together per-site likelihoods over the resampled sites. Otherwise, the tree parameters are optimized on the resampled data (FULL). The resampled likelihood differences are denoted , where i indexes the replicate, and they are subsequently transformed by subtracting the mean resampled difference <Δ'>, a procedure called centering. The original difference in likelihoods is compared with the null distribution in a one-tailed, non-parametric manner, whereby the rank of Δ is evaluated against the centered, sorted Δ' distribution. If the rank of Δ is found to lie outside the interval of the null distribution between 0 and the (1-α) × 100 percentile, the difference in likelihoods is significant with (1-α) × 100% confidence, and the null hypothesis is rejected in favor of the alternative. (The acceptable type I, or false positive, error rate per test is denoted α.)
Here the tree topologies are ML phylogenies that represent different regions of the HCV genome. The reference alignment of 38 HCV whole-genome sequences representing 18 confirmed subtypes (Table 1) was obtained from the LANL HCV database . We conducted SH tests with data from the 5' UTR, the Okamoto region of NS5B, and whole genome. Topologies were paired such that the ML tree inferred from the data of region x (either the 5' UTR or Okamoto region) was compared with the ML tree from data of region y representing each other region (either 5' UTR, Okamoto region, polypeptide, or whole genome, provided y ≠ x), yielding the likelihood difference Δ ≡ L x () - L x (), where L x () is the likelihood of the ML tree from region y evaluated with data from region x. We randomly resampled 10,000 replicate data sets for each pair of trees and compared the original difference in likelihoods with the null distribution that resulted. The type I error rate was reduced to accommodate six hypothesis tests (α = 0.05/6 = 0.00833). This reduction preserves the experiment-wide false-positive rate by making each comparison more stringent.
Consistency and homoplasy indices
To understand better phylogenetic inconsistencies over the HCV genome, we computed the character consistency index (CI) for each site in PAUP with the whole-genome phylogeny, and summarized CI with a moving-window (running) average over 100, 300, and 500 nt. The 100 nt window size was used subsequently because it allows for clear visualization of the 342 nucleotides that constitute the 5' UTR. Because the consistency and homoplasy indices (HI) are complementary (CI+HI = 1), character consistency is high when homoplasy is low, and vice versa. Thus, we expect lower homoplasy to result from fewer informative sites. Further, homoplasy decreases rapidly with decreasing substitution rates. To control for variation in the number of informative sites across the genome, we rescaled the homoplasy index against the square of the proportion of informative sites in the window region. This was done because, in the limit of short branch lengths, the number of informative sites should be proportional to the substitution rate r, while the number of homoplasies should be proportional to r2. The result was subsequently normalized against the maximum, to facilitate comparison with the proportion of informative sites. As a result, if all parts of the HCV genome are equally informative, one can expect the rescaled homoplasy index to be roughly constant over the viral genome.
This work was supported by an NIH-DOE interagency agreement (Y1-A1-1500-04) and a LANL internal directed research grant for vaccine design. We thank T-10 and both the HCV and HIV database teams at LANL for sharing their resources and expertise, and particularly Bette Korber for helpful discussions. LA-UR 06-3473.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002,347(13):975-982. 10.1056/NEJMoa020047View ArticlePubMedGoogle Scholar
- Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM: Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C - A randomized study of treatment duration and ribavirin dose . Ann Intern Med 2004,140(5):346-355.View ArticlePubMedGoogle Scholar
- Simmonds P: Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol 2004, 85: 3173-3188. 10.1099/vir.0.80401-0View ArticlePubMedGoogle Scholar
- Weck K: Molecular methods of hepatitis C genotyping. Expert Rev Mol Diagn 2005,5(4):507-520. 10.1586/14737184.108.40.2067View ArticlePubMedGoogle Scholar
- Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A: Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005,42(4):962-973. 10.1002/hep.20819View ArticlePubMedGoogle Scholar
- Major ME, Rehermann B, Feinstone SM: Hepatitis C viruses. In Fields' Virology. 4th edition. Edited by: Knipe DM, Howley PM. Philadephia , Lippincott, Williams & Wilkins; 2001:1127-1161.Google Scholar
- Yusim K, Richardson R, Tao N, Dalwani A, Agrawal A, Szinger J, Funkhouser R, Korber B, Kuiken C: Los Alamos hepatitis C immunology database. Appl Bioinformatics 2005,4(4):217-225. 10.2165/00822942-200504040-00002View ArticlePubMedGoogle Scholar
- Roffi L, Redaelli A, Colloredo G, Minola E, Donada C, Picciotto A, Riboli P, Del Poggio P, Rinaldi G, Paris B, Fornaciari G, Giusti M, Marin R, Morales R, Sangiovanni A, Belloni G, Pozzi M, Poli G, Mascoli N, Corradi C, Pioltelli P, Scalori A, Mancia G: Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype. Eur J Gastroenterol Hepatol 2001,13(5):501-506. 10.1097/00042737-200105000-00007View ArticlePubMedGoogle Scholar
- Felsenstein J: Inferring Phylogenies. Sunderland, MA , Sinauer Associates; 2004.Google Scholar
- Swofford DL, Olsen GJ, Waddell PJ, Hillis DM: Phylogenetic inference. In Molecular Systematics. 2nd edition. Edited by: Hillis DM, Moritz C, Mable BK. Sunderland, MA , Sinauer Associates; 1996:407-514.Google Scholar
- Simmonds P: Variability of hepatitis C virus. Hepatology 1995,21(2):570-583. 10.1016/0270-9139(95)90121-3View ArticlePubMedGoogle Scholar
- Salemi M, Vandamme AM: Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. J Mol Evol 2002,54(1):62-70. 10.1007/s00239-001-0018-9View ArticlePubMedGoogle Scholar
- Farris JS, Källersjö M, Kluge AG, Bult C: Testing significance of incongruence. Cladistics 1994, 10: 315-319. 10.1111/j.1096-0031.1994.tb00181.xView ArticleGoogle Scholar
- Chan SW, McOmish F, Holmes EC, Dow B, Peutherer JF, Follett E, Yap PL, Simmonds P: Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 1992, 73: 1131-1141.View ArticlePubMedGoogle Scholar
- Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, Saeed AA, Holmes EC: Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 1993, 74: 661-668.View ArticlePubMedGoogle Scholar
- Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, Simmonds P: The origin of hepatitis C virus genotypes. J Gen Virol 1997, 78: 321-328.View ArticlePubMedGoogle Scholar
- Yang Z, Lauder IJ, Lin HJ: Molecular evolution of the hepatitis B virus genome. J Mol Evol 1995,41(5):587-596. 10.1007/BF00175817View ArticlePubMedGoogle Scholar
- Posada D, Crandall KA: Selecting models of nucleotide substitution: an application to human immunodeficiency virus 1 (HIV-1). Mol Biol Evol 2001,18(6):897-906.View ArticlePubMedGoogle Scholar
- Smith DB, Simmonds P: Characteristics of nucleotide substitution in the hepatitis C virus genome: Constraints on sequence change in coding regions at both ends of the genome. J Mol Evol 1997,45(3):238-246. 10.1007/PL00006226View ArticlePubMedGoogle Scholar
- Thurner C, Witwer C, Hofacker IL, Stadler PF: Conserved RNA secondary structures in Flaviviridae genomes. J Gen Virol 2004, 85: 1113-1124. 10.1099/vir.0.19462-0View ArticlePubMedGoogle Scholar
- Walewski JL, Gutierrez JA, Branch-Elliman W, Stump DD, Keller TR, Rodriguez A, Benson G, Branch AD: Mutation Master: Profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions. RNA 2002,8(5):557-571. 10.1017/S1355838202029023PubMed CentralView ArticlePubMedGoogle Scholar
- Tuplin A, Wood J, Evans D, Patel A, Simmonds P: Thermodynamic and phylogenetic prediction of RNA secondary structures in the coding region of hepatitis C virus. RNA 2002,8(6):824-841. 10.1017/S1355838202554066PubMed CentralView ArticlePubMedGoogle Scholar
- Simmonds P, Tuplin A, Evans DJ: Detection of genome-scale ordered RNA structure (GORS) in genomes of positive-stranded RNA viruses: implications for virus evolution and host persistence. RNA 2004,10(9):1337-1351. 10.1261/rna.7640104PubMed CentralView ArticlePubMedGoogle Scholar
- Schultes E, Hraber PT, LaBean TH: Global similarities in nucleotide base composition among disparate functional classes of single-stranded RNA imply adaptive evolutionary convergence. RNA 1997,3(7):792-806.PubMed CentralPubMedGoogle Scholar
- Richter SS: Laboratory assays for diagnosis and management of hepatitis C virus infection. J Clin Microbiol 2002,40(12):4407-4412. 10.1128/JCM.40.12.4407-4412.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Chen Z, Weck KE: Hepatitis C virus genotyping: interrogation of the 5' untranslated region cannot accurately distinguish genotypes 1a and 1b. J Clin Microbiol 2002,40(9):3127-3134. 10.1128/JCM.40.9.3127-3134.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Laperche S, Lunel F, Izopet J, Alain S, Dény P, Duverlie G, Gaudy C, Pawlotsky JM, Plantier JC, Pozzetto B, Thibault V, Tosetti F, Lefrère JJ: Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol 2005,43(2):733-739. 10.1128/JCM.43.2.733-739.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Laperche S, Saune K, Dény P, Duverlie G, Alain S, Chaix ML, Gaudy C, Lunel F, Pawlotsky JM, Payan C, Pozzetto B, Tamalet C, Thibault V, Vallet S, Bouchardeau F, Izopet J, Lefrère JJ: Unique NS5b hepatitis C virus gene sequence consensus database is essential for standardization of genotype determinations in multicenter epidemiological studies. J Clin Microbiol 2006,44(2):614-616. 10.1128/JCM.44.2.614-616.2006PubMed CentralView ArticlePubMedGoogle Scholar
- Halfon P, Trimoulet P, Bourliere M, Khiri H, Lédinghen V, Couzigou P, Feryn JM, Alcaraz P, Renou C, Fleury HJA, Ouzan D: Hepatitis C virus genotyping based on 5' noncoding sequence analysis (Trugene). J Clin Microbiol 2001,39(5):1771-1773. 10.1128/JCM.39.5.1771-1773.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Sandres-Sauné K, Deny P, Pasquier C, Thibaut V, Duverlie G, Izopet J: Determining hepatitis C genotype by analyzing the sequence of the NS5b region. J Virol Methods 2003,109(2):187-193. 10.1016/S0166-0934(03)00070-3View ArticlePubMedGoogle Scholar
- Lole KS, Jha JA, Shrotri SP, Tandon BN, Prasad VG, Arankalle VA: Comparison of hepatitis C virus genotyping by 5' noncoding region- and core-based reverse transcriptase PCR assay with sequencing and use of the assay for determining subtype distribution in India. J Clin Microbiol 2003,41(11):5240-5244. 10.1128/JCM.41.11.5240-5244.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Shukla DD, Hoyne PA, Ward CW: Evaluation of complete genome sequences and sequences of individual gene products for the classification of hepatitis C viruses. Arch Virol 1995,140(10):1747-1761. 10.1007/BF01384339View ArticlePubMedGoogle Scholar
- Forns X, Maluenda MD, Lopez-Labrador FX, Ampurdanes S, Olmedo E, Costa J, Simmonds P, Sanchez-Tapias JM, Anta MTJD, Rodes J: Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients. J Clin Microbiol 1996,34(10):2516-2521.PubMed CentralPubMedGoogle Scholar
- Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001,345(1):41-52. 10.1056/NEJM200107053450107View ArticlePubMedGoogle Scholar
- Colina R, Casane D, Vasquez S, García-Aguirre L, Chunga A, Romero H, Khan B, Cristina J: Evidence of intratypic recombination in natural populations of hepatitis C virus. J Gen Virol 2004, 85: 31-37. 10.1099/vir.0.19472-0View ArticlePubMedGoogle Scholar
- Moreau I, Hegarty S, Levis J, Sheehy P, Crosbie O, Kenny-Walks E, Fanning LJ: Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland. Virology J 2006, 3: 95. 10.1186/1743-422X-3-95View ArticleGoogle Scholar
- Torres-Puente M, Bracho MA, Jimenez N, Garcia-Robles I, Moya A, Gonzalez-Candelas F: Sampling and repeatability in the evaluation of hepatitis C virus genetic variability. J Gen Virol 2003, 84: 2343-2350. 10.1099/vir.0.19273-0View ArticlePubMedGoogle Scholar
- Alfonso V, Mbayed VA, Sookoian S, Campos RH: Intra-host evolutionary dynamics of hepatitis C virus E2 in treated patients. J Gen Virol 2005, 86: 2781-2786. 10.1099/vir.0.81084-0View ArticlePubMedGoogle Scholar
- Roque-Afonso AM, Ducoulombier D, Di Liberto G, Kara R, Gigou M, Dussaix E, Samuel D, Feray C: Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol 2005,79(10):6349-6357. 10.1128/JVI.79.10.6349-6357.2005PubMed CentralView ArticlePubMedGoogle Scholar
- Swofford DL: PAUP*. Phylogenetic analysis using parsimony (* and other methods). 4th edition. Sunderland, MA , Sinauer Associates; 2002.Google Scholar
- Felsenstein J: Distance methods for inferring phylogenies: a justification. Evolution 1984, 38: 16-24. 10.2307/2408542View ArticleGoogle Scholar
- Gascuel O: BIONJ: an improved version of the NJ algorithm based on a simple model of sequence data. Mol Biol Evol 1997,14(7):685-695.View ArticlePubMedGoogle Scholar
- Posada D, Crandall KA: ModelTest: testing the model of DNA substitution. Bioinformatics 1998,14(9):817-818. 10.1093/bioinformatics/14.9.817View ArticlePubMedGoogle Scholar
- Burnham KP, Anderson DR: Model selection and multimodel inference: a practical information-theoretic approach. 2nd edition. New York , Springer-Verlag; 2002.Google Scholar
- Posada D, Crandall KA: Selecting the best-fit model of nucleotide substitution. Syst Biol 2001,50(4):580-601. 10.1080/106351501750435121View ArticlePubMedGoogle Scholar
- Hansen MH, Yu B: Model selection and the principle of minimum description length. J Am Stat Assoc 2001,96(454):746-774. 10.1198/016214501753168398View ArticleGoogle Scholar
- Akaike H: A new look at the statistical model identification. IEEE Trans Automatic Control 1974,19(6):716-723. 10.1109/TAC.1974.1100705View ArticleGoogle Scholar
- Shimodaira H, Hasegawa M: Multiple comparisons of log-likelihoods with applications to phylogenetic inference. Mol Biol Evol 1999,16(8):1114-1116.View ArticleGoogle Scholar
- Goldman N, Anderson JP, Rodrigo AG: Likelihood-based tests of topologies in phylogenetics. Syst Biol 2000,49(4):652-670. 10.1080/106351500750049752View ArticlePubMedGoogle Scholar
- Kuiken C, Yusim K, Boykin L, Richardson R: The Los Alamos hepatitis C sequence database. Bioinformatics 2005,21(3):379-384. 10.1093/bioinformatics/bth485View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.